INTRODUCTION
Genomic amplification is a common mechanism leading to deregulated gene expression in human cancers. In neuroblastoma, MYCN amplification has been found to correlate with aggressive tumour growth and can serve as a predictor of clinical outcome [1, 2] . There is evidence that amplification rather than up-regulation of basal expression is the main mechanism for the loss of autoregulation of MYCN [3] and its overexpression [4, 5] . However, it is not clear how MYCN amplification results in poor outcome [6] [7] [8] . It is possible that coamplification of other DNA sequences plays a role in the poor outcome of MYCN amplified tumours.
Although the MYCN amplicon is known usually to involve coamplification of extensive regions of DNA, only the DEAD-box gene DDX1, to date, has been identified as being frequently coamplified with MYCN in neuroblastoma [9, 10] . We have implemented an approach for the two-dimensional (2-D) separation of human genomic restriction fragments to detect novel genomic alterations in neuroblastoma cell lines and primary tumours [11, 12] . The 2-D approach allows the identification and isolation of as yet unknown amplified sequences. The use of the enzyme NotI to digest DNA and the tagging of the fragments at the NotI ends allow preferential visualization and quantitative analysis of fragments containing CpG islands. Using this approach we have recently cloned a novel gene referred to as NAG, that is frequently coamplified with MYCN in neuroblastoma [13] . We report here the identification and cloning of two additional CpG islands that are amplified in neuroblastoma. One is identified as containing the first intron of DDX1, and the other represents a novel CpG island that is associated with an as yet unidentified gene. We show that the novel CpG island is frequently coamplified with MYCN.
2-D Gel Analysis
A detailed description of the experimental conditions can be found in [11] . Briefly, genomic DNA was digested with NotI and EcoRV restriction enzymes, and the NotI derived 5Ј protruding ends were 32 P-labeled. After first-dimensional separation of the fragments in agarose disc gels, a second digestion was done in situ with DpnII. The resulting fragments were separated perpendicularly in a polyacrylamide gel. 2-D gels were dried and exposed to PhosphoImager plates (Molecular Dynamics, Sunnyvale, CA). Digital images were obtained after scanning of the PhosphoImager plates.
Cloning of the Amplified DNA Fragments
DNA fragments were cloned from preparative gels as previously described [11] . Briefly, both radiolabeled and and peripheral blood lymphocytes from the patient from whose tumor the cell line was derived (right). Large arrows point to spots with increased intensity owing to the fragments being amplified. Thin lines join pairs of spots whose fragments share the same NotI restriction site. The names for genes are shown in parentheses. Small arrows point to fragments from tandemly repeated DNA that is often demethylated in neuroblastomas [11, 23] . nonradiolabeled genomic digests of cell line STA-NB-11 were loaded onto first-dimension agarose gels. After the second-dimension separation in polyacrylamide, the gels were exposed to X-ray film. The NotI/DpnII fragments corresponding to the DNA spots of interest were recovered and ligated in a NotI/BamHI digested pBC-vector (ClonTech, Palo Alto, CA) in the presence of DNA ligase at 16°C for 40 hr. The transformation was performed by electroporation with the Epicurian Coli XL1-Blue MRF electroporation-competent cells (Stratagene, La Jolla, CA).
RESULTS AND DISCUSSION 2-D DNA Electrophoresis Identifies CpG Islands Frequently Coamplified With MYCN in Neuroblastoma
We have undertaken an initial 2-D DNA electrophoresis analysis for six neuroblastoma cell lines. The 2-D patterns obtained were compared to a series of more than 200 patterns of a variety of normal tissues and other malignant and nonmalignant cell lines in order to identify multicopy fragments that are derived from amplified DNA in the neuroblastoma cell lines. Five NotI/DpnII fragments designated NBA-1A, -1B, 2A, -2B, and -3 ( Fig.  1) were present in multiple copies only in neuroblastoma cell lines that contain an amplified MYCN gene as determined by Southern analysis. However, none of the five fragments was derived from the MYCN gene; the latter yields, with the enzyme combination utilized, fragments of >10 kb that are outside the first-dimension separation range.
Two fragments designated NBA-2A and -2B were recently cloned and shown to be part of a novel gene, which we have cloned and referred to as NAG [13] . NAG was shown to be frequently coamplified with MYCN. In this study we cloned the three other multicopy Not/DpnII fragments NBA-1A, -1B, and -3 from preparative 2-D gels as described in Materials and Methods. The cloned fragments were sequenced, and the novel sequences were compared to a known sequences from the EMBL database. Starting at the NotI site a stretch of 181 bp of the 290 bp fragment NBA-3 was identical with a CpG island in the database. This sequence also matches the sequence for the first intron of DDX1 (R. Godbout, personal communication). Fragments NBA-1A and -1B showed no significant homology with any of the known sequences in the database. Using the 253 bp fragment NBA-1A as a probe, we isolated a BAC clone (BAC14876). A 6.3 kb PstI fragment of this BAC clone that encompassed NBA-1A was subcloned. Partial sequence analysis of the subclone revealed that the 287 bp fragment NBA-1B is en- compassed in the BAC subclone and that fragments NBA-1A and -1B contained (one at its 5Ј end and the other at its 3Ј end) the same NotI restriction site and will thus be referred to together as NBA-1. Approximately 1,023 bp of the BAC subclone sequence surrounding the NotI site revealed the characteristics of a CpG island with a C and G content of 65% of the nucleotides and a CpG/GpC ratio of 0.61. Thus it is likely that NBA-1 represents a novel CpG island that is associated with an as yet unidentified gene. Using the BAC clone as probe, we performed fluorescence in situ hybridization (FISH) on metaphases of neuroblastoma cell line NGP127 (Fig.  2) , which exhibits amplification of the NBA-1 fragment. Bright signals are observed at the chromosome bands 2p23-24 confirming the localization of NBA-1 in close vicinity to the locus of the MYCN gene. Furthermore, hybridization signals in the HSR integrated at chromosome band 4p16 confirmed the coamplification of NBA-1 with MYCN in the HSR of this cell line [19] .
Comparison of the Frequency of Coamplification of DDX1, NAG, and fragment NBA-1 With MYCN
Because NBA-1 was found to be amplified in three of the four MYCN-amplified neuroblastoma cell lines in our initial analysis, it was likely that this CpG island is frequently encompassed in the MYCN amplicon in neuroblastoma as DDX1 and NAG. To compare the frequency of coamplification of DDX1, NAG, and the newly cloned CpG island with MYCN, we utilized for Southern analysis the cloned NotI/DpnII fragments NBA-3 and NBA-2A, and NBA-1A as probes for DDX1, NAG, and the newly cloned CpG island, respectively (Figs. 3, 4) . A total of 10 neuroblastoma cell lines and a total of 65 neuroblastoma tumor samples were analyzed. Amplification of either of the three fragments was found only in neuroblastomas that were also amplified for MYCN. In two of the eight MYCN-amplified cell lines (STA-NB-4 and STA-NB-11) and in five of thirteen MYCN-amplified tumors, all three fragments were amplified. In three cell lines (IMR-32, STA-NB-3, STA-NB-8) and in four tumours, both DDX1 and NAG were coamplified with MYCN. Cell lines NGP-127 and STA-NB-9 and the remaining four MYCNamplified tumors showed coamplification of only the NBA-3 fragment with MYCN. Thus we found that DDX1 and NAG were coamplfied in five of eight (62%) cell lines and in nine of thirteen (70%) of the tumors, and there were no cases in which one was amplified without the other. The NBA-1 CpG island was coamplified with MYCN in four of eight (50%) of the cell lines and nine of thirteen (70%) of the tumours. Cell line KCNR but none of the tumors showed amplification of only the MYCN gene.
The MYCN amplicon contains two NotI sites located less then 50 kb from each other, within a 500 kb region at the 5Ј end of MYCN [20] . It is likely that the CpG islands of DDX1 and NAG, which were always coamplified in our series of neuroblastomas, contain the two NotI restriction sites. The CpG island encompassed by fragment NBA-1 shows a partly overlapping but distinct pattern of coamplification compared to DDX1 and NAG. Thus it may be presumed that NBA-1 is located at the 3Ј end of MYCN. According to Akiyama et al. [20] , the closest NotI site 3Ј of MYCN has been found at a distance of 680 kb.
Amplification of MYCN is a well-established prognostic factor in neuroblastoma, and ovenexpression of MYCN can contribute to cell transformation [21] and targeted expression of MYCN results in neuroblastoma in transgenic mice [22] . However, given that the MYCN amplicon contains additional genes including DDX1, NAG, or yet a third gene associated with the CpG island NBA-1, the heterogeneity in the MYCN amplicon may influence the biology of neuroblastoma.
